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Introduction 
Since 2008, gonorrhoea diagnoses have been increasing in England, with 41,193 new cases 
reported in 2015 [1]. Despite this, population prevalence of gonorrhoea remains low [2, 3]. 
Infection is concentrated in high risk groups, including men who have sex with men (MSM) 
and black Caribbeans [1]. Consequently, gonorrhoea prevalence in people attending 
specialist sexual health services (also known as Genitourinary Medicine Clinics, hereafter 
referred to as “specialist SHSs”), which typically serve higher-risk populations, may be 
higher than in those attending other community-based SHSs, such as contraception clinics, 
pharmacies or general practice [2].  
 
Testing for gonorrhoea in community SHSs has become widespread, in part due to the 
availability of dual nucleic acid amplification tests (NAATs), which detect N. gonorrhoeae and 
Chlamydia trachomatis simultaneously [4]. A 2013 survey found that over half of regional 
local government administrative organisations in England (known as local authorities (LAs)) 
use dual NAATs within their chlamydia screening programmes, which aim to diagnose and 
control chlamydia in sexually active people aged 15–24 years [4, 5]. However, if infection 
prevalence is low, so is the positive predictive value (PPV) of the test, leading to many false 
positive test results. Confirmatory testing (defined as a supplementary NAAT with a different 
nucleic acid target) increases the PPV of the testing algorithm thereby minimising the risk of 
misdiagnoses and unnecessary treatment and partner notification, and in England is 
recommended for populations where the testing algorithm results in a PPV below 90% [6]. 
Unnecessary treatment is detrimental to individual patients, both emotionally and physically, 
but is also problematic at the population level because unnecessary use of antibiotics may 
contribute to the increase of antimicrobial resistance. 
Unfortunately, data on gonorrhoea prevalence in those attending community SHSs in 
England are sparse. The lack of local data may complicate decision-making by sexual health 
commissioners and service providers about gonorrhoea testing and associated care 
pathways in community SHSs. We used available surveillance data to develop a model 
estimating gonorrhoea prevalence in heterosexual men and women aged 15-24 attending 
community SHSs in LAs across England to inform the design of testing care pathways. 
 
Methods 
Data sources and study period 
All specialist and a minority of community SHSs in England routinely report data on 
gonorrhoea diagnoses among those tested to the Genitourinary Medicine Clinic Dataset 
(GUMCADv2) [7]. GUMCADv2 data for 2015 was used to calculate the gonorrhoea 
prevalence in heterosexual men and women aged 15-24 years attending specialist and 
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community SHSs that routinely test heterosexual men and women aged 15-24 for 
gonorrhoea (all specialist SHSs and community SHSs that conduct ≥50 tests per year). 
Gonorrhoea prevalence by patient LA of residence was calculated by dividing the total 
number of gonorrhoea diagnoses by the total number of gonorrhoea tests.  
 
Analysis 
Linear and quadratic regression models were used to quantify the relationship between 
gonorrhoea prevalence in those attending specialist versus community SHSs for LAs with 
data available from both service types. Model fit was assessed using the R2 value and t-
tests. Initial analysis suggested model-fit was improved by stratifying LAs according to 
patient residence within or outside London. The best fitting models were applied to the 
national surveillance data (GUMCADv2) from specialist services in the remaining LAs to 
estimate gonorrhoea prevalence in heterosexual patients aged 15-24 years in their 
respective community SHSs. These estimations and the manufacturers’ test sensitivity and 
specificity data [8] were used to calculate the PPV of the initial (reactive) gonorrhoea test 
result for tests conducted in community SHSs for each LA [9]. PPVs were calculated using 
the following equation: (sensitivity*prevalence)/((sensitivity*prevalence)+(1-specificity)*(1-
prevalence)). Analyses were completed in STATA v13. 
 
On-line tool to support 
The best fit models developed in this analysis to predict gonorrhoea prevalence and 
associated PPV were converted into a user-friendly excel tool to support commissioners and 
service providers in making decisions about gonorrhoea testing (Supplementary material). 
When users select a LA, the tool presents the following local data: reported or estimated 
gonorrhoea prevalence, the estimated PPV of the initial (reactive) test and estimated number 
of false and true positives per 1000 tests performed. The tool also suggests whether or not 
supplementary testing is recommended to confirm infection (based on the recommended 
90% threshold outlined in the UK gonorrhoea testing guidance [6]) and presents revised 
estimate of the PPV following supplementary testing. The estimated PPV after 
supplementary testing was calculated using the PPV equation stated above, except the 
prevalence is calculated using the following equation: estimated number of false 
positives/(estimated number of false positives + estimated number of false negatives).  
 
Results 
We identified 102 out of 326 LAs (29/33 in London and 73/293 outside London) with data on 
gonorrhoea prevalence in young heterosexual men and women attending community SHSs. 
This included data from 227 specialist SHSs (33 in London and 194 outside London) and 
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102 community SHSs (29 in London and 73 outside London).  Overall, 260,499 gonorrhoea 
tests were reported (specialist SHSs: 112,306 in London and 99,339 outside London; 
community SHSs: 17,003 in London and 31,851 outside London) and 3,783 gonorrhoea 
diagnoses were made (specialist SHSs: 1,958 in London and 1,388 outside London; 
community SHSs: 293 in London and 144 outside London). 
 
Estimated gonorrhoea prevalence in community services 
In 29 LAs in London, the median gonorrhoea prevalence was 1.7% (mean 1.8, range 0.7-
3.5%) in young heterosexuals attending specialist SHSs and 1.3% (mean 1.5%, range 0.0-
4.3%) in young heterosexuals attending community SHSs. A best-fit quadratic regression 
model identified a weak positive association between gonorrhoea prevalence in community 
and specialist SHSs in London (R2 = 0.13, p=0.058; Figure 1A). Using this model, median 
gonorrhoea prevalence in young heterosexuals attending all community services in London 
was estimated to be 1.4% ((0.14*specialist service prevalence2)+1.01; mean 1.5%, range 
1.0-2.7%). 
 
In 73 LAs outside of London, the median gonorrhoea prevalence was 1.1% (mean 1.3%, 
range 0.0-5.3%) in young heterosexuals attending specialist SHSs and 0.2% (mean 0.5%, 
range 0.0-6.6%) in young heterosexuals attending community SHSs. A best-fit linear 
regression model identified a positive association between gonorrhoea prevalence in 
community and specialist SHSs outside London (R2 = 0.07, p=0.02; Figure 1B). Using this 
model, median gonorrhoea prevalence in young heterosexuals attending all community 
services outside London was estimated to be 0.4% ((0.3*specialist service 
prevalence)+0.17; mean 0.5, range 0.2%-1.7%). 
 
Overall in England, gonorrhoea prevalence among young heterosexuals tested in specialist 
SHSs was ≤1% in half of LAs (160/326; 49.0%). Gonorrhoea prevalence among young 
heterosexuals tested in community SHSs was estimated to be ≤1% in the majority of LAs 
(285/326; 87.4%).  
 
Estimated PPVs of reactive test results  
In London, the median gonorrhoea prevalence in young heterosexuals attending specialist 
SHSs was 1.7% and estimated to be 1.4% in community SHSs. The median PPV for a 
reactive test result was 63.1% in specialist SHSs and was estimated to be 58.4% in 
community SHSs. Outside London, the median gonorrhoea prevalence was 1.1% in 
specialist SHSs and estimated to be 0.4% in community SHSs. The median PPV for a 
reactive test result was 52.4% in specialist SHSs and was estimated to be 28.4% in 
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community SHSs. Using these prevalence data, the estimated number of false positives and 
negatives and PPV estimates are presented in Table 1. 
 
Discussion 
We have developed a simple method to estimate gonorrhoea prevalence in young 
heterosexual men and women attending community SHSs in England, which can be used by 
sexual health commissioners and service providers to inform decisions about gonorrhoea 
testing in their local populations. A user-friendly tool based on the models developed is 
available online [6]. Our method is easily reproducible in other countries with high quality 
surveillance data and is of value to identify populations in which the PPVs of the initial 
(reactive) tests will be low, leading to increased risk of misdiagnoses and unnecessary 
interventions. 
 
Although our models showed significant correlations in gonorrhoea prevalence in different 
clinical settings within the same LA, there remained considerable unexplained variation. 
Predicting gonorrhoea prevalence at the LA level may mask concentrated pockets of high 
prevalence associated with the distribution of higher risk populations. Overlooking these 
clusters may result in missed opportunities for gonorrhoea testing in populations where there 
is a need, particularly if these groups are less likely to attend specialist SHSs. Additionally, 
these models do not estimate gonorrhoea prevalence in the general population, they are 
specific to heterosexuals populations, aged 15 to 24 years, attending SHSs. These patients, 
including those attending for chlamydia screening, are not a random sample of the 
population and are likely to be at higher risk of gonorrhoea infection than the general 
population. 
 
Future analyses should include covariate information (currently not well completed in 
community SHSs) and consider modelling prevalence to a lower geographic level, such as 
lower super output area (LSOA). Furthermore, the models used assumed all areas outside 
of London are similar. However, there are distinct and important differences in service use 
and population demographics across and within LAs, both inside and outside of London. We 
have also not developed models to predict gonorrhoea prevalence in MSM because there 
were too few gonorrhoea tests and diagnoses reported amongst MSM attending community 
SHSs. This is partly due to incomplete reporting and  because MSM being more likely to 
attend a specialist rather than community SHSs for STI testing [10]. It is likely that these data 
would improve the precision of our model in estimating gonorrhoea prevalence within 
specific populations and thereby enable more targeted testing. 
 
6 
 
In this study, we assumed that reported gonorrhoea diagnoses in GUMCADv2 are confirmed 
diagnoses (i.e. have undergone supplementary testing). This might mean that we have 
overestimated gonorrhoea prevalence, and in turn overestimated the initial test PPV. 
However, since the prevalence is very low in most settings our principle findings are unlikely 
to be altered. 
 
Our analyses suggest that gonorrhoea prevalence in heterosexual men and women 
attending community SHSs in England is low, especially outside London. In all community 
and almost all specialist SHSs, the PPV of reactive gonorrhoea test results would be below 
the recommended 90% threshold outlined in the UK gonorrhoea testing guidance [6]. 
Introducing gonorrhoea testing in community SHSs, including existing chlamydia screening 
programmes, may improve service provision and gonorrhoea detection in populations that 
do not attend specialist SHSs [11]. However, our analyses suggest that in most community 
services, the majority of reactive test results would be false positives.  
 
A recent study estimating gonorrhoea prevalence in the general population, where 
prevalence in those aged 16-44 years was <0.1%,  showed that only five of 26 initial reactive 
test results could be confirmed, giving a PPV of 19% [3]. Likewise, data from Australia 
strongly suggest that an apparent rise in gonorrhoea diagnoses in women was due to an 
increase in false positive results following deployment of gonorrhoea NAATs in low 
prevalence populations [12]. Our study supports the principle that in all community SHSs, 
and, indeed, in most specialist SHSs,  care pathways for gonorrhoea testing should include 
supplementary testing to reduce the risk of misdiagnosis, inappropriate patient management, 
and unnecessary treatment [6]. Our methodology and findings are likely to be relevant to 
many other world regions where gonorrhoea prevalence in the general population is low.  
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Table 1: Estimated prevalence and associated positive predictive value (PPV), false 
positives and negatives after an initial (reactive) gonorrhoea test, plus the estimated 
PPV after supplementary testing 
 
Estimated 
prevalence 
Median PPV 
of initial 
(reactive) test 
Estimated 
number of 
false 
positives in 
1000 tests 
Estimated 
number of 
false 
negatives in 
1000 tests 
Estimated PPV 
after 
supplementary 
testing 
London services 
Specialist 1.7% 63.1% 10 17 99.4% 
Community 1.4% 58.4% 10 14 99.3% 
Outside London services 
Specialist 1.1% 52.4% 10 11 99.1% 
Community 0.4% 28.4% 10 4 97.5% 
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Supplementary material 1 
Example of gonorrhoea positive predict value (PPV) estimate toolkit available and updated online: 2 
https://www.gov.uk/government/publications/guidance-for-the-detection-of-gonorrhoea-in-england 3 
(example data presented) 4 
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Local authority
GUM test 
PPV
Supplementary 
testing 
recommended?
GUM test PPV after 
supplementary 
testing
64.8% YES 99.5%
Community 
test PPV
Supplementary 
testing 
recommended?
Community test 
PPV after 
supplementary 
testing
29.1% YES 97.6%
0.00413823
4
Camden
1.8% 99.0% 99.0% 10                                    
Locally determined 
gonorrhoea prevalence 
in community settings
Specificity of 
community 
tests
Estimated number of false 
positives in 1000 tests
0.4% 99.0% 99.0% 10                                    
18
Locally determined 
gonorrhoea prevalence 
in GUM attendees
Estimated gonorrhoea 
prevalence in 
community settings
Sensitivity of 
community 
tests
Estimated number of true 
positives in 1000 tests
Making decisions about gonorrhoea testing
Toolkit estimating the positive predictive value (PPV) of Neisseria gonorhoeae tests 
in community and GUM settings by lower tier local authority
Estimated gonorrhoea 
prevalence in GUM 
attendees
Sensitivity of 
GUM tests
Specificity of 
GUM tests
Estimated number of false 
positives in 1000 tests
Estimated number of true 
positives in 1000 tests
Toolkit instructions
To estimate the postive predictive value of gonorrhoea tests in community and GUM settings, please follow the instructions below.
 Click on the yellow box and select the lower tier local authority of interest from the drop down menu. All cells will change depending on the local authority 
selected except for test sensitivity and specificity values, and locally determined prevalence option cells.
 You may enter your own estimates of gonorrhoea prevalence for community and GUM settings in the orange cells. You may also enter your own estimates 
of test sensitivity and specificity if more accurate data are available from your local laboratory. If text is entered in these cells it will override the existing 
data.
 You may also enter other estimates for the test sensitivity and specificity in the blue cells.
Background
The prevalence of  Neisseria gonorrhoeae in 15-24 year old patients resident in the selected lower tier local authority and tested in the community is estimated 
from the prevalence of N. gonorrhoeae in 15-24 year old patients resident in the same lower tier local authority and tested in any GUM clinic. Early modelling 
work (still in development) has found the prevalence of N. gonorrhoeae in the community to be approximately one third of the prevalence in GUM settings.1 
The postive predictive value (PPV) (the probability that N. gonorrhoeae is present when the test is positive) for tests in GUM and the community have been 
calcuated using this estimated value of true prevalence using data from 2012. In the column labelled 'Supplementary testing recommended?' there is a 
statement of whether confirmation of tests conducted in the community or GUM setting is advised. This recommendation is yes if the estimated community or 
GUM tests PPV is less than 90%.
Part of the statistical algorithm in this tool uses prevalence estimates from some published studies that do not confirm test results, potentially overestimating 
the true prevalence of N. gonorrhoeae in the community. This algorithm will be reviewed quarterly and refreshed when new data are available.
1. Town K, Furegato M, Hughes G. Developing a method to estimate the prevalence of Neisseria gonorrhoeae in community based sexual health services to 
inform decisions on gonorrhoea testing. International Union against STIs; 2014 European conference, Malta  
Calculations used:
PPV=(sensitivity*prevalence)/(sensitivity*prevalence)+((1-specificity)*(1-prevalence))
Number of false positives in sample of 1000 tests=(1-specificity)*((1-prevalence)*1000)
Sources of data used in the predictive model:
Rao GG, Bacon L, Evans J, et al. Prevalence of Neisseria gonorrhoeae infection in young subjects attending community clinics in South London. Sex Transm 
Infect 2008;84:117–21
Skidmore S, Copley S, Cordwell D, et al. Positive nucleic acid amplification tests for Neisseria gonorrhoeae in young people tested as part of the National 
Chlamydia Screening 3. Programme. Int J STD AIDS 2011;22:398–9
Lavelle SJ, Jones KE, Mallinson H, et al. Finding, confirming, and managing gonorrhoea in a population screened for chlamydia using the Gen-Probe Aptima 
Combo2 assay. Sex Transm Infect 006;82:221–4
Fowler T, Edeghere O, Inglis N, et al. Estimating the positive predictive value of opportunistic population testing for gonorrhoea as part of the English 
Chlamydia Screening Programme. Int J STD  AIDS 2013:24:185–91
Newcastle, North Tyneside and Northumberland Chlamydia Screening Programme dual testing data
Genitourinary Medicine Clinic Activity Dataset version 2 (all GUM clinics and some Level 2 services)
Acknowledgments: We'd like to thank Dr Nigel Field, Alireza Talebi, Holly Mitchell, Dr Kirsty Foster and Dr André Charlett for their support and contribution of 
data to the toolkit.
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